ALK (Anaplastic lymphoma kinase) rearrangement is the second most common targetable oncogene-dirven gene in NSCLC (non-small cell lung cancer). It is identified in approximately 3–7% of NSCLC patients [ [1] ], and is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, ceritinib, brigatinib [ [2] ]. EML4-ALK rearrangement was firstly identified by Soda et al. in 2007 [ [3] ]. With the development of NGS (Next Generation Sequencing), more and more novel ALK fusion partners have been identified, such as KIF5B, STRN, KLC1, TPR, HIP1, DCTN1, CMTR1, GCC2, SEC31A and so on. A liquid biopsy by amplicon-based NGS analysis has been considered as an accurate and reliable tool to detect and monitor clinically relevant molecular alterations. Herein, using NGS and malignant pleural effusion (MPE) cfDNA, we report a novel latent transforming growth factor β binding protein 1 (LTBP1)-ALK fusion in a patient with NSCLC. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2020.03.025
Authors: HuiWen Qian, Juan Li, LiRong Zou, Cheng Ji, Hayen Li, YuShuang Zheng, LingChuan Guo, WeiDong Zhu, Yi Zhang
